Skip to main content
SpringerLink
Log in

Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goeree R, Levin L. Building bridges between academic research and policy formulation: the PRUFE framework. An integral part of Ontario’s evidence-based HTPA process. Pharmacoeconomics 2006; 24: 1143–1156

    Article  PubMed  Google Scholar 

  2. Program for Assessment of Technology in Health (PATH) [online]. Available from URL: http://www.path-hta.ca/ [Accessed 17 Dec 2006]

  3. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. Can Med Assoc J 2005; 173: 345–351

    Article  Google Scholar 

  4. Bowen J, Hopkins R, He Y, et al. Systematic review and cost-effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario: interim report for the Ontario Ministry of Health and Long Term Care. Hamilton (ON): Program for Assessment of Technology in Health, McMaster University, 2005. Report No. HTA002-0512. Contract No. 06129 [online]. Available at URL: http://www.path-hta.ca/DESreport.pdf [Accessed 17 Dec 2006]

    Google Scholar 

  5. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 2006; 62: 2091–2100

    Article  PubMed  Google Scholar 

  6. Laupacis A. Inclusions of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Can Med Assoc J 2002; 166: 44–47

    Google Scholar 

  7. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute of Clinical Excellence, 2004

    Google Scholar 

  8. Williams A. The economic role of’ health indicators’. In: Teeling Smith G, editor. Measuring the social benefit of medicine. London: Office of Health Economics, 1983: 63–67

    Google Scholar 

  9. Birch S, Gafni A. Cost-effectiveness/utility analysis: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–296

    Article  PubMed  CAS  Google Scholar 

  10. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis)application of economics to the real world. J Health Econ 1993; 12: 469–476

    Article  PubMed  CAS  Google Scholar 

  11. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 1993; 148: 913–917

    CAS  Google Scholar 

  12. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should’ reasonable decisions’ lead to uncontrolled growth in expenditures? Can Med Assoc J 2003; 168: 849–851

    Google Scholar 

  13. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics, 2003; 21: 149–157

    Article  PubMed  Google Scholar 

  14. Birch S, Gafni A. The biggest bang for the buck or the bigger bucks for the bang: the fallacy of a cost effectiveness threshold. J Health Serv Res Pol 2006; 11: 46–51

    Article  Google Scholar 

  15. Naylor CD. Cost-effectiveness analysis: are the outputs worth the inputs? ACP J Club 1996; 124: A12–A14

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest relevant to this manuscript. No funding was received for the preparation of this paper.

Author information

Authors and Affiliations

  1. Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada

    Amiram Gafni & Stephen Birch

  2. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

    Amiram Gafni & Stephen Birch

Authors
  1. Amiram Gafni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Birch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gafni, A., Birch, S. Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More. Pharmacoeconomics 25, 523–528 (2007). https://doi.org/10.2165/00019053-200725060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725060-00007

Keywords

Search

Navigation